Compare FuelCell Energy Inc (FCEL) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

FuelCell Energy (FCEL) trades at $14.16, down 13.5% over 24 hours, reflecting negative momentum amid ongoing operational losses. The stock exhibits a bearish technical signal, with key support at $14. Recent financials show revenue of $158.16M in 2025 but a net loss of $187.90M, with negative gross and net income margins. Analyst consensus is split evenly between Buy and Hold, with a $21.57 price target. Multiple law firms have announced securities class actions related to disclosures from June to September 2026, adding legal overhangs.

FCEL's outlook remains challenged by persistent unprofitability and cash burn, though analyst targets suggest potential upside from current levels. Key risks include the class action lawsuits, execution on scaling power agreements, and the company's ability to achieve positive cash flow. The stock presents a high-risk opportunity contingent on operational turnaround and resolution of legal issues.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.